📢 Free Webinar: The 10th Annual Drugs & Devices Australia Webinar – 2024
We invite you to join our Director Sarah Griffin and Lucid Health Consulting – Experience Matters. Director George Papadopoulos for their much-anticipated webinar on the latest developments in reimbursement strategies for the Australian market.
📅 When: 28 November, 8:30am AEST and 27 November 2024, 1:30pm PST.
During this session, George and Sarah will share valuable insights on navigating the complex landscape of drug and device reimbursement applications. Together, they will review the key trends from the past year and address your questions live during the webinar.
Why Attend?
✳ Stay up-to-date on the latest changes in Australia’s reimbursement policies
✳ Get a comprehensive overview of the Australian Healthcare Landscape in 2024
✳ Ask questions and get answers from industry leaders
This webinar is eagerly anticipated, don’t miss your chance to attend this informative session. Register Now by clicking here to register 🔗 REGISTER FOR THE 10TH ANNUAL DRUGS & DEVICES 2024 WEBINAR HERE
Upon registration, you’ll receive a confirmation email with details on how to join the webinar.
We look forward to sharing our expertise, reflecting on the past year, and engaging with you during our 10th Annual Drugs & Devices Australia Reimbursement Update.
ABOUT THE SPEAKERS
Sarah Griffin, Director at MedTechnique Consulting 
Sarah is Founder and Director at MedTechnique Consulting. She is an experienced health economist, reimbursement strategist, health policy advocate and speaker. Connect with Sarah Griffin on LinkedIn.
If you would like to learn more about Sarah’s speaking experience for your next event please email: Kim MacDonald, Spindrift Marketing
George Papadopoulos is Director at Lucid Health Consulting.
George is a healthcare pricing and reimbursement professional with over 30 years’ experience across in local and international healthcare companies. George worked in both local operating company and global levels in increasing levels of responsibility for leading pharmaceutical companies in Australia, Belgium and the United States.